Clinical trials: Genotype
Hepatitis C
Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment
The purpose of this study is to test the potential antiviral efficacy of triple-combination therapy with Peginterferon α-2b + ribavirin + boceprevir (PRB) in patients with HCV genotype 3 who previously failed Peginterferon α +…
- Trial name
- LeeG3 (NCT01585584)
- Testing
- Boceprevir
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- University of Calgary
Hepatitis C Virus
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
The purpose of this study is to evaluate the efficacy of 6 or 8 weeks of treatment regimen containing simeprevir (SMV), daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naive (not having received treatment with any approved or…
- Trial name
- ACCORDION-1 (NCT02349048)
- Testing
- Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg
- Where
- 8 sites in United States, Canada
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
Drug Interactions
Influence of OATP1B1 and CYP2C9 Genotypes on the Pharmacokinetics of Bosentan Before and During Clarithromycin
The aim of the present study is to assess the impact of the OATP1B1 genotype (SLCO1B1*15 vs. wild type; ~2% SLCO1B1*15 haplotypes in Caucasian population) and the CYP2C9 genotype (*2 and *3 allele vs.
- Trial name
- NCT01425229
- Testing
- Bosentan
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Gerd Mikus
Chronic Hepatitis C
Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)
The primary objective of this study is to determine the safe and effective dose range of boceprevir (SCH 503034) in combination with PEG-Intron in adult subjects who have chronic hepatitis C without cirrhosis, and who have failed…
- Trial name
- NCT00160251
- Testing
- Boceprevir (BOC), PegIntron (PEG), Ribavirin (RBV)
- Volunteers
- 357 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)
This is a controlled, randomized, parallel-groups, open-label, multinational study designed to evaluate the efficacy and safety of PEG-Intron® (pegylated interferon alfa-2b) plus Rebetol® (ribavirin) in subjects with chronic…
- Trial name
- NCT00265395
- Testing
- Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®), Combination of pegylated interferon alfa-2b and ribavirin
- Volunteers
- 1,428 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C
This 4-arm study will compare the efficacy and safety of PEGASYS induction and maintenance dosing, versus standard fixed dosing in combination with Copegus, and the efficacy and safety of higher dose versus standard dose Copegus…
- Trial name
- NCT00394277
- Testing
- peginterferon alfa-2a, Ribavirin
- Where
- 184 sites in United States, Belgium and 13 more
- Volunteers
- 1,175 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Virus Infection
Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis
This study is to evaluate the antiviral efficacy, safety, and tolerability of combination therapy with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) + vedroprevir (VDV) ± ribavirin (RBV) for 8 weeks in…
- Trial name
- NCT02226549
- Testing
- LDV/SOF, VDV, RBV
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic Pain
Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants
The study is to investigate whether alisporivir (ALV; DEB025) alone or in combination with either ribavirin (RBV) or peginterferon alfa-2a (PEG) is more efficient compared to standard of care (PEG+RBV) in treatment-naïve…
- Trial name
- NCT01215643
- Testing
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Where
- 73 sites in United States, Australia and 12 more
- Volunteers
- 340 people
- Sponsor
- Debiopharm International SA
Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1
Trial in Adult Participants With Spinocerebellar Ataxia (SCA)
The primary purpose of this study was to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in participants with spinocerebellar ataxia (SCA).
- Conditions
- Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1, Spinocerebellar Ataxia Genotype Type 2, Spinocerebellar Ataxia Genotype Type 3
- Trial name
- NCT02960893
- Testing
- Troriluzole
- Where
- 18 sites in United States
- Volunteers
- 141 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Respiratory Failure, Hepatitis C
Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant
This is a proof of concept, single center study for the donation of HCV-positive lungs to HCV negative recipient patients, with preemptive, interventional treatment with 8 weeks of commercially available DAA therapy to prevent…
- Trial name
- NCT03625687
- Testing
- Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Hepatitis C Virus
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)
The purpose of this study in HCV genotype 4-infected participants with compensated cirrhosis is to assess the safety and to compare the percentage of participants achieving a 12-week sustained virologic response (SVR12), [HCV…
- Trial name
- AGATE-1 (NCT02265237)
- Testing
- ombitasvir/paritaprevir/ritonavir, ribavirin
- Volunteers
- 184 people
- Sponsor
- AbbVie
Hepatitis C, Chronic
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
The substances BI 201335 and BI 207127 are being developed for the treatment of chronic hepatitis C virus infection. BI 201335 and BI 207127 work by preventing the virus from replicating.
- Trial name
- NCT01132313
- Testing
- BI 207127, BI 201335, Ribavirin
- Where
- 53 sites in United States, Australia and 8 more
- Volunteers
- 488 people
- Sponsor
- Boehringer Ingelheim
Hepatitis C Virus (HCV)
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection
This study seeks to assess the safety and efficacy of treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in non-cirrhotic, genotype 1a (GT1a) hepatitis C virus infected participants who are…
- Trial name
- GEODE II (NCT02609659)
- Testing
- ombitasvir/paritaprevir/ritonavir and dasabuvir, ribavirin
- Volunteers
- 105 people
- Sponsor
- AbbVie
Chronic Hepatitis C
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir
The purpose of this study is to evaluate the safety and tolerability of AL-335 in combination with odalasvir (ODV) with or without simeprevir (SMV) in participants with genotype (GT)1 or GT2 or GT3 chronic hepatitis C (CHC)…
- Trial name
- NCT02569710
- Testing
- AL-335, Odalasvir (ODV), Simeprevir (SMV)
- Where
- 11 sites in Mauritius, Moldova and 2 more
- Volunteers
- 161 people
- Sponsor
- Alios Biopharma Inc.
Hypertension
Pharmacogenetic Prediction of Metoprolol Effectiveness
The investigators will prospectively follow a population of patients with uncontrolled high blood pressure beginning metoprolol succinate therapy to determine the drug effect in an observational clinical trial.
- Trial name
- NCT02293096
- Testing
- metoprolol succinate, Genotyping, CYP2D6 Phenotyping
- Where
- United States
- Volunteers
- 462 people
- Sponsor
- University of Colorado, Denver
Hepatitis C, Chronic
Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243)
The objective of the study is to evaluate the effectiveness of PegIntron plus Rebetol combination in treating patients with chronic hepatitis C in a primary care setting.
- Trial name
- PRACTICE (NCT00709059)
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 538 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia, Memory Disorders
The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype
This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Atomoxetine is a drug that has been Food and Drug Administration (FDA) approved for Attention Deficit…
- Conditions
- Schizophrenia, Memory Disorders, Cognition Disorders
- Trial name
- Atomoxetine (NCT00548327)
- Testing
- Atomoxetine, Functional magnetic resonance imaging, Neuropsychological Testing
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Hepatitis C
BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C
The purpose of this study is to compare the rates of sustained virologic response in each cohort (Black-African Americans, Latinos) in this study to historical rate.
- Trial name
- NCT01389323
- Testing
- Daclatasvir, Peg-Interferon Alfa-2a, Ribavirin
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 448 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment
The study is to investigate whether participants with hepatitis C virus (HCV) genotype 1 who have a history of non-response/relapse to peginterferon alfa-2a (PEG) and ribavirin (RBV) may benefit from treatment with triple therapy…
- Trial name
- NCT01183169
- Testing
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Where
- 75 sites in United States, Australia and 12 more
- Volunteers
- 459 people
- Sponsor
- Debiopharm International SA
Asthma, Gastroesophageal Reflux
Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma
This study will evaluate the effect of CYP2C19 and ABCB1 genes on pharmacokinetics of lansoprazole in children with mild gastroesophageal reflux (GER) and uncontrolled asthma.
- Trial name
- GenARA (NCT03015610)
- Testing
- commercially available lansoprazole
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Jason Lang, M.D., M.P.H.